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I am humbled by the kind words of introduction of
President-Elect Frank Padberg, and I feel privileged to
stand here as the fifteenth president of the American Ve-
nous Forum (AVF). It is an honor to follow the footsteps of
my predecessors, 14 great surgeons, who provided leader-
ship in the past to this respected society.
As we learned from our historians, the idea of the AVF
started in 1987, at the fourth European-American Sympo-
sium on Venous Disease, organized in Bethesda, Md, by
Drs Leonel Villavicencio, Norman Rich, John Bergan, and
Charles Rob. Encouraged by the success of this symposium
and supported by the Joint Council of the Vascular Societ-
ies, a group of 20 distinguished surgeons, our founding
fathers (Table I) from North America, decided to form a
scientific society for venous disease. The Forum was
founded in an era when academic meetings allotted little
time to venous research, when venous disease was consid-
ered much less important than arterial disease, and when in
the family of vascular surgeons those who practiced venous
surgery had the disadvantaged position of a stepchild.
During the past 15 years our society has become one of
the most respected societies in the world for venous disease.
We have developed into an international forum for venous
research, and as our society strengthened, so did recogni-
tion of venous surgery and, more recently, of endovenous
interventions. Venous surgery is no longer considered to be
a stepchild of vascular surgery; it is, without doubt, an equal
partner to arterial surgery. I have been privileged to follow
the changes in the past two decades and enjoyed, with many
of my colleagues, contributing in whatever modest way to
the progress of this challenging field.
PERSONAL REFLECTIONS
Presidential addresses are opportunities to remind us of
our heritage, review the current state of our profession, and
focus our attention on changes promising a brighter future.
Before I speak on my rich institutional heritage and some
aspects of our venous surgical practice, I feel it is most
appropriate to thank some people who are closest to my
heart because they helped me to get where I am today: my
parents, my wife, and my children. Without them I would
have never succeeded. As you learned in the introduction of
Dr Padberg, I was born and raised in communist Hungary.
My father, Zolta´n, was a physician—a family practitioner,
the best I have ever met. He was board-certified in both
internal medicine and neurology. He and my mother, Eva,
had five children, and they raised us with love and gave us
an excellent education. My father, a compassionate and
hard-working physician, taught me to love my patients and
stand up for my principles. My father passed away a couple
of years ago, but my mother lives in good health in Buda-
pest. I thank my parents for everything they did for me. I
am also thankful to my wife, Marta, for her love and
support, and for our two beautiful children, Peter and Julia,
who believe that heritage is important, since both, born in
Minnesota, speak Hungarian fluently.
MENTORS
One constant in the three decades of my surgical career
has been my commitment to venous surgery. My mentors
played a major role in it, as mentors influence trainees in
selection of surgical specialties tremendously. For choosing
vascular surgery and being devoted to venous surgery, I
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would like to thank Professor Lajos Soltesz at the Semmel-
weis Medical School in Budapest, Hungary. Professor Solt-
esz, a pioneer vascular surgeon who was instrumental in
establishing an independent board of vascular surgery in
Hungary as early as 1980, ran a very busy vascular practice.
I spent many hours at his outpatient clinic; he was the first
to teach me that vascular disease includes arterial, venous
and lymphatic problems, and that vascular surgeons should
take care of varicose veins, chronic venous ulcers, lymphed-
ema, and vascular malformations as well as carotid artery
disease or aortic aneurysms. At his clinic, in the early 70s, I
met some giants in venous surgery. One was Professor
Malan from Italy, a pioneer in the field of vascular malfor-
mations.1 Another visitor I vividly remember was Robert
May from Austria, who talked to us on his study with
Thurner on compression of the left iliac vein by the right
iliac artery.2 He gave me a first hand account of a venous
disorder we all call today the May-Thurner syndrome.
In spite of the communist rule in the mid 70s, Soltesz
succeeded in sending me to Paris for over a year to work
with both Professors Servelle and Cormier. Servelle had
extensive experience with patients who had arteriovenous
malformations, Klippel-Trenaunay syndrome, lymphed-
ema, and chylous effusions.3,4 I had a chance to see many
patients with these rare problems. Cormier also had an
interest in venous malformations, but he was also an expert
in venous thrombectomy and in venous reconstructions.5,6
It was in Paris, that I first got interested in lymphatic
microsurgery and wrote my thesis, “Experimental lym-
phovenous anastomoses.”7 Professor Servelle, who was a
student of Rene Leriche, frequently talked to us about
American surgery. When I asked him about the one place in
the United States I should visit, the answer was always the
same: “La Clinique de Mayo, Monsieur Peter,” he told me.
It took me five more years, but I ended up in Rochester,
Minn, at the Mayo Clinic, with the Bestor scholarship, to
become the first research fellow of Dr Larry Hollier, who
had just established a new practice and soon after a new
Section of Vascular Surgery. Here I met my other mentors,
subsequent vascular division chairs at Mayo, Peter C. Pai-
rolero and Kenneth J. Cherry. I am most thankful for their
guidance and friendship. I should also mention my other
colleagues with whom I have worked at Mayo in the past
two decades in vascular surgery: John W. Hallett, Thomas
C. Bower, Jean Panneton, Audra A. Noel, and Timothy M.
Sullivan. It has been a privilege to be part of this team, and
I thank them for their support and friendship.
One of my great role models in surgery, Oliver Beahrs,
once wrote, “A surgeon’s approach to surgery is not his
Fig 1. A, Charles H. Mayo (1865-1939), one of the founders of the Mayo Clinic, who performed the first operation
in the United States for varicose veins in 1988. B, External vein stripper, used by Charles H. Mayo in 1906. By
permission of Mayo Historical Unit, Mayo Foundation, Rochester, Minn.
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alone but is a composite of the best of what he has seen and
learned in the course of his educational experience.”8 I
consider as mentors those surgeons who gave me their time
and education during my traveling as the EJ Wylie Travel-
ing Fellow and the Cheselden Visiting Professor. I am
thankful to them for contributing to my education.
VENOUS SURGERY AT THE MAYO CLINIC
Institutional heritage is important and most stimulat-
ing in the career of an academic surgeon. Patrick Henry said
in 1775, “I have but one lamp by which my feet are guided,
and that is the lamp of experience. I know no way of
judging of the future but the past.” I found a great history
of venous surgery at the Mayo Clinic and I would like to
share with you some of the historical details. Founded at
the turn of the century by the two sons of William W.
Mayo, Drs Will and Charlie Mayo, the Mayo Clinic was the
first integrated multidisciplinary practice in medicine based
on the principle that the best interest of the patient is the
only interest considered. Venous surgery at the Mayo
Clinic developed from two different roots. One was the
unique surgical heritage of varicose vein surgery. The other
was modern cardiovascular surgery, which started in the
1950s headed by John W. Kirklin and later by Dwight
McGoon.
The importance of venous disease was recognized
early by the Mayo brothers. Shortly after graduating
from Northwestern University in 1988, Charles H.
Mayo was the first to perform an operation in the United
States for varicose veins.9 In 1906 he reported on 181
patients operated on for varicose veins with an external
venous stripper (Fig 1, A and B).10 For the first time in
history, a Vein Service was founded in 1917, headed by
Dr Frederick L. Smith. This surgical Vein Service
achieved national and international recognition under
the leadership of Dr Thomas T. Myers (Fig 2), who
became the head of the section in 1947. He was later
joined by Drs Karl A. and Eric P. Lofgren (Fig 3, A and
B). Myers advocated extensive operation for varicose
veins and developed the modern stripping method with
the invention of a flexible intra-luminal stripper, the
prototype of the currently used disposable vein strip-
pers.11 During their years at Mayo, Myers and the
Lofgren brothers performed over 18,000 operations for
varicose veins.9 They treated patients with deep venous
insufficiency and venous ulcers, and observed and treated
hypertensive ulcers, congenital venous malformations,
Fig 2. Thomas T. Myers (1906-1980), head of the Section of
Peripheral Vein Surgery of the Mayo Clinic between 1947 and
1966. Courtesy of Mayo Foundation.
Fig 3. A, Eric P. Lofgren (born 1919) and B, Karl A. Lofgren
(born 1915), prolific vein surgeons from the Mayo Clinic. Cour-
tesy of Mayo Foundation.
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superficial thrombophlebitis, and acute deep venous
thrombosis. Their landmark study on 1000 consecutive
patients, who underwent operation for varicose veins
with a follow-up of 10 years, was published by Karl A.
Lofgren and established vein stripping as the standard for
treatment of varicose veins.12 The group also studied the
effect of stripping on venous physiology by using ambu-
latory venous pressure measurements, and they called
attention to the reversed orientation of valves in the foot
perforators. When the Section of Vascular Surgery was
formally established in 1983 by Dr. Larry H. Hollier, all
venous surgery was soon taken over by vascular surgeons,
who have performed superficial, open, and endoscopic
perforator vein surgery in addition to deep and central
vein reconstructions.13-17
Operations on the superior and inferior vena cava were
first performed by cardiovascular surgeons. Kirklin replaced
the superior vena cava with homograft in 1955. Surgical
treatment of superior vena syndrome was further developed
by Philip E. Bernatz. This exceptional thoracic and vascular
surgeon used Ivalon and Dacron grafts for superior vena
cava reconstructions in the 1950s and reported them in
1962.18 Large vein reconstructions were more frequently
performed later by Pairolero, Hollier, and by our
team.13,16,17 Bower and Nagorney reported on large expe-
rience of vena cava replacement performed in conjunction
with major liver resection for malignant tumors.15 Today,
venous surgery is an equal partner with arterial surgery at
Mayo. Patients with venous disease are treated in the
unique practice model of a vascular center.
Fig 4. A, The Gonda Building of the Mayo Clinic houses the Vascular Center that opened in 2002. Courtesy of Mayo
Foundation.
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VASCULAR CENTER—THE MAYO MODEL OF
CARE
Although vascular centers function at other institutions
in the United States as well as abroad and there are different
effective models, it is worthwhile to say a few words about
the Mayo model of vascular care. The Gonda Vascular
Center opened in 1991 with the goal to provide a single site
for coordinated, comprehensive, and multidisciplinary
evaluation of patients with vascular disease. Two of the
previous directors, John W. Hallett and Thom W. Rooke,
deserve special recognition. It is due to their visionary
leadership that this outpatient facility soon became a busy
center for evaluation and ambulatory treatment of patients
with vascular diseases, with associated inpatient vascular
medicine and attached surgery and interventional radiology
services.19 In 2002, the Center moved to the new Gonda
Building, where it occupies a superb physical space of an
area of 32,000 square feet (Fig 4, A and B). It functions as
a multidisciplinary vascular disease program, independent
of departments and divisions, with its own administrative
multidisciplinary leadership and a separate budget. The
medical team includes 35 physicians and 65 allied health
staff primarily from Vascular Medicine, Vascular Surgery,
and Diagnostic and Interventional Radiology. Other spe-
cialties involved include Cardiology, General Internal Med-
icine, Dermatology, Physical Medicine, and Hematology.
The center is devoted to providing state-of-the-art diagno-
sis and treatment for patients with acute and chronic dis-
eases affecting the arteries, veins, and the lymphatic system.
In 2002, 25,071 patients underwent evaluation or treat-
ment at the Gonda Vascular Center. Fig 5 lists the full
spectrum of services provided to patients with venous dis-
ease. The benefits of the center concept are obvious: it is
disease- and patient-centered, and patients can consult with
specialists of different background to make the most in-
formed decisions on medical, endovascular, or surgical
care. The model follows the commitment of the Mayo
Clinic that the needs of the patient come first, and the
approach to patient care, education, and research is multi-
disciplinary and integrated. It is the Center’s vision that it is
recognized as one of the best centers for diagnosis and
treatment of vascular disease, and its mission is to provide
the best vascular care and services to our patients and
function in an efficient and cost-effective manner. It is in
this environment, that I had the fortune to develop my
venous practice in the past two decades, with special atten-
tion to those patients who present with chronic venous
valvular incompetence and deep vein occlusions. The de-
mand for venous care has been enormous and it is con-
stantly increasing. Chronic venous disease needs and de-
serves more attention than what is devoted to it in most
medical institutions in the United States.
CHRONIC VENOUS DISEASE—A PUBLIC
HEALTH PROBLEM
One main objective of the AVF during the past 15 years
has been to improve treatment and quality of life of patients
with chronic venous disease of the lower limbs. Chronic
venous disease is a spectrum of venous problems ranging
from simple varicose veins at one end to severe, multilevel
Fig 4 (Continued). B, The lobby of the Gonda Vascular Center. Courtesy of Mayo Foundation.
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venous insufficiency and venous ulcers at the other. It is one
of the most prevalent of medical conditions. An estimated
20 to 25 million Americans have varicose veins, 2.5 million
have advanced chronic venous insufficiency, and about 1
million have venous ulcers. New epidemiologic data from
Olmsted County20 estimates the incidence of advanced
chronic venous insufficiency to be 76.1 per 100,000 per-
son-years and the incidence of venous ulcerations to be 18
per 100,000 person years, with women being more fre-
quently affected then men (20.4 vs 14.6). A sobering
finding was that the incidence of venous ulcers was un-
changed in the past two decades in females and it recently
increased in males. In the United States each year over
20,000 new ulcer patients are treated, 12% of them require
hospitalization, and the annual costs of ulcer patients has
been estimated to be between $150 million to 1 billion
dollars.21 During the past 15 years the AVF had several
initiatives to establish guidelines22-24 and to define report-
ing standards on the treatment of patients with chronic
venous disease,25-27 and progress in this field has been
reviewed by previous presidents of this society.28-32 It
continues to be our obligation to advance the science of
medical care in this difficult field, to collect data and publish
information for physicians, patients, and the public on
evidence of efficacy of the emerging technology.
THE ENDOVENOUS REVOLUTION
Minimally invasive endoscopic and endovascular tech-
nology has changed the way we treat vascular disease, but
few areas in surgery have seen such rapid transformation in
the past few years as the field of venous disease. En-
dovenous techniques have revolutionized treatment of pa-
tients with venous disease. Ultrasound-guided endovenous
ablation of the great saphenous vein with radiofrequen-
cy33,34 and laser35 has challenged the classic dogma of
saphenous stripping and high ligation. Ultrasound-guided
foam sclerotherapy of the great saphenous vein is another
promising technique with clinical trials just completed in
Europe and multicenter studies ready to be launched in the
United States. Endovenous recanalization and stenting of
large veins have obviated the need for open surgical bypass
surgery for many patients.36 Endovenous technology ad-
vanced rapidly for treatment of acute deep vein thrombosis
as well, using catheter directed thrombolysis, mechanical
thrombectomy, and stents.31,37
The aim of treatment of patients with chronic venous
disease is to correct the underlying venous abnormality to
decrease ambulatory venous hypertension. Ablation of the
superficial reflux remains the main focus of treatment.
Open surgery still has a lot to offer patients with chronic
venous disease. It is the proven way to treat varicose veins,
and different techniques of minimally invasive inversion
stripping combined with high ligation of the tributaries
remain our current standard for treatment of superficial
reflux.38 Varicose tributaries are treated with phlebectomy
or sclerotherapy. There is not much doubt, however, that
endovenous therapy for ablation of the incompetent saphe-
nous vein with radiofrequency-, laser- or ultrasound-
guided foam sclerotherapy are new techniques here to
stay.34,35 Long-term results of these treatment modalities
are not yet available, but the early benefit of endovenous
ablation versus surgery has recently been confirmed in one
prospective, randomized study (EVOLVES).35 Endo-
scopic treatment with subfascial endoscopic perforator sur-
gery (SEPS) continues to be a superior technique to open
interruption of the incompetent perforating veins;14 its role
in post-thrombotic patients is not well-defined, and benefit
in a soon-to-be-published European randomized study was
not demonstrated. SEPS and sclerotherapy of incompetent
perforators need to be compared for efficacy. Treatment of
deep-vein incompetence continues to be a difficult task;
open or angioscopic valve repair, vein transposition, and
transplantation are available techniques; still, most are prac-
ticed only by special experts in the field.39-41 Open venous
bypass is reserved for patients who failed or who are not
candidates for endovascular treatment; results are more
Fig 5. Programs and services provided to patients with venous and lymphatic diseases at the Gonda Vascular Center.
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durable when autologous vein is used for bypass.13,16,42
Early and midterm results of venous stents used for iliac
vein occlusion are very promising.36 The endovenous rev-
olution will bring its mostly awaited result, however, when
percutaneous treatment of deep-vein valve incompetence is
possible with stents containing competent valves. This
technique at present is still in the experimental phase.
Research in our society should be directed to this most
important field.
THE AMERICAN VENOUS FORUM—MAIN
OBJECTIVES
The AVF has been a society distinguished by 15 years of
academic excellence. Our main objectives continue to be to
advance basic and clinical research in venous disease and to
provide quality meetings, postgraduate courses, and edu-
cational materials to our members and to physicians inter-
ested in venous disorders. Our annual meeting and the
attached postgraduate course define current standards of
venous disease management. The AVF is ideally positioned
to conduct prospective, multicenter clinical studies to eval-
uate new venous technology. We should be among the first
to embrace endovenous and endoscopic technology and
conduct swift prospective studies in centers of academic
excellence to endorse or reject new techniques offered to
our patients. It should be our task to educate our venous
specialists on indications and new techniques of manage-
ment. We have other important objectives as well. The AVF
and its educational partner, the AVF Foundation should
intensify efforts to increase public awareness on prevention
and treatment of acute and chronic venous disease. The
spirit of the Forum demands collaboration with other ve-
nous specialists, and members of other vascular societies.
We should strengthen communications with other vascular
surgical and venous organizations, and provide leadership
on venous disease management within the Society for Vas-
cular Surgery, the International Union of Angiology, the
International Society of Endovascular Therapy, and the
International Union of Phlebology. Finally, with increasing
need to introduce expensive technology for minimally in-
vasive therapy, it is imperative for us to work with and to
improve our relations with industry to develop new tech-
nology and support of our mission.
To be successful, we also have to grow. One of the
benefactors of the Mayo Clinic, Mr Leslie Gonda, once said
that if the old oak does not grow, it dies. We need to grow
to have a strong voice in the management of venous disease.
Endovenous and minimally invasive technology is popular
among our young members and vascular fellows, so let’s
profit by new technologies and entice our young surgeons
to introduce them in their clinical practice. We should focus
on education of our young members and increase educa-
tional support for vascular fellows.
The AVF had a very successful first 15 years and we are
ready for the next 15 years. I know the talent of this society
and I feel its power. There is no progress without change,
but we should stand up to protect proven surgical therapy
of venous disease. At the same time, we must be ready to
test new technology and quickly adopt the effective mini-
mally invasive and endovenous techniques. We should also
be ready to train the next generation of venous specialists,
for the benefit and protection of our specialty, for the future
of this distinguished society, and for the benefit of our
patients with venous disease. I am asking you to keep
venous surgery where it belongs: let it be an integral part of
vascular interventions and an equal partner to arterial sur-
gery. Ladies and gentlemen, it has been a singular honor
and a distinct privilege to serve as president of the AVF
during the past year, and I thank you for the opportunity.
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